[2023. 10. 26.][NYSE:CANF]Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Can-Fite BioPharma Partners with CPI to Revolutionize Cancer Drug Development Using AI and ML
PETACH TIKVA, Israel–(BUSINESS WIRE)– In a groundbreaking collaboration, Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) has joined forces with Collaborations Pharmaceuticals, Inc. (CPI) to harness the power of artificial intelligence (AI) and machine learning (ML) in the development of cutting-edge anti-cancer drugs. This partnership aims to expedite the creation of next-generation A3 adenosine receptor drug agonists, ultimately reducing both time and costs associated with bringing these crucial drugs to market.
Leveraging their state-of-the-art MegaSyn generative AI method, CPI will employ AI and ML tools to design novel molecules with superior affinity and selectivity for the A3AR target identified by Can-Fite. CPI will also be responsible for the chemical synthesis of these newly designed molecules, paving the way for the development of innovative and robust anti-cancer drug candidates. Can-Fite will then take the lead in testing these candidates for their anti-cancer effects and validating their molecular mechanisms.
Prof. Pnina Fishman, Executive Chairman and CSO at Can-Fite, shared her vision for the project, stating, “Our vision is to deliver in silico small molecule drug candidates in a better and faster way to patients via a collaboration with Collaborations Pharmaceuticals. Our accumulated experience of bringing anti-cancer drugs which target the A3AR from lab to patients will be implemented into this AI drug development project.”
Sean Ekins, PhD, DSc., CEO and Founder of Collaborations Pharmaceuticals, Inc., expressed his enthusiasm for the partnership, saying, “We are delighted that Can-Fite chose our team of experts for this AI-led drug discovery collaboration and look forward to demonstrating what our technology can do. We also look forward to complementing their outstanding scientific approach with our integrated technology platform and ability to generate novel and selective molecules.”
Can-Fite BioPharma Ltd. is at the forefront of clinical stage drug development, with a focus on oncology, liver disease, and inflammatory conditions. The company’s lead drug candidate, Piclidenoson, has recently reported promising results in a Phase III trial for psoriasis and is poised to enter a pivotal Phase III stage. Can-Fite’s other drugs, including Namodenoson, are also undergoing clinical trials for various indications, including hepatocellular carcinoma and steatotic liver disease.
Collaborations Pharmaceuticals, Inc., known for its MegaSyn generative drug design technology, has developed innovative software tools for data curation and machine learning. They are actively engaged in research and development for therapeutics in rare and neglected diseases.
Forward-Looking Statements: This press release contains forward-looking statements regarding Can-Fite’s expectations and business prospects. These statements are inherently subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. Can-Fite undertakes no obligation to update or review forward-looking statements.
For more information, please visit Can-Fite BioPharma’s official website: www.can-fite.com.
About Collaborations Pharmaceuticals: Learn more about Collaborations Pharmaceuticals, Inc. at http://www.collaborationspharma.com/.